This core will provide Projects 1, 2 and 3 as well as the Antibody Core with necessary influenza virus reagents to conduct the proposed research. All three Projects as well as the Antibody Core will greatly benefit from this core's ability to produce a large panel of high quality recombinant influenza virus hemagglutinin and neuraminidase proteins as well as chimeric versions of these molecules. These proteins are functional, correctly folded and glycosylated and will be used in various assays by Project 1. 2 and 3 and as baiting agent by the Antibody Core. Furthermore, the core will produce custom made recombinant viruses that express chimeric hemagglutinin, neuraminidase and chimeric neuraminidase proteins in the influenza A and B virus background. Project 1 will use these viruses for analysis of monoclonal antibodies and for mimicking of preexisting immunity in animal models. Finally, the Reagent Core will supply Projects 1, 2 and 3 as well as the Antibody Core with high titer virus stocks, mouse adapted influenza virus challenge strains and purified virus preparations
The Reagent Core will provide recombinant proteins and viruses that have been developed in the Palese laboratory and are not available from any other source. These reagents are essential for the research conducted in Projects 1. 2 and 3.
|Wohlbold, Teddy John; Krammer, Florian (2014) In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6:2465-94|
|Ellebedy, Ali H; Krammer, Florian; Li, Gui-Mei et al. (2014) Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 111:13133-8|
|Tan, Gene S; Lee, Peter S; Hoffman, Ryan M B et al. (2014) Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol 88:13580-92|
|Nachbagauer, Raffael; Wohlbold, Teddy John; Hirsh, Ariana et al. (2014) Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-8|